echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Antitumor Therapy > Anti-tumor new drug diphatopyl pyreth in the United States approved clinical!

    Anti-tumor new drug diphatopyl pyreth in the United States approved clinical!

    • Last Update: 2020-08-14
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Recently, Shenzhen Haiwang Bioengineering Co., Ltd. announced that its wholly-owned subsidiary, Shenzhen Haiwang Pharmaceutical Science and Technology Research Institute Co., Ltd., in the research of the new anti-tumor drug "xylene sulphate padvance tablets" (acceptance number: IND134903) clinical research application on January 19, 2018 by the United States Food and Drug Administration approved (the "U.S. FDA" ) to allow it to conduct clinical research in the United States.
    xylene sulfonate protinib is the first target anti-small cell lung cancer drug in China for the absence of eGFR19 exoon, no. 21 external onset mutation. The announcement indicates that the company has independent intellectual property rights over xylene sulfonate poutini and tablets, and no identical products are currently available in China.
    from the similar product market, the foreign-listed same-target drug is Germany's Bollinger Ingham in 2013 listed Gilotrif (Afatini), the domestic has not yet been listed. According to the company's annual report, Gilotrif had global sales of $231 million in 2015.
    .
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.